Pfizer has discontinued the Phase III trial A4021018 (ADVIGO 1018), which examined the investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC). An independent Data Safety Monitoring Committee (DSMC) recommended the trial be stopped, concluding that the addition of figitumumab to erlotinib is unlikely to demonstrate a statistically significant...